• Skip to primary navigation
  • Skip to main content
AMRA MedicalAMRA Medical

AMRA Medical

Precision for Decision

  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Set Up
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Media
  • About Us
    • About AMRA
    • Our Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us

Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders – Quantitative Skeletal Muscle MRI in Clinical Trials

September 23, 2020
  • Facebook
  • Twitter
  • LinkedIn
  • Mail

WEDNESDAY, OCTOBER 7, 2020 @ 11:00 AM – 12:30 PM EDT

Drug development in neuromuscular disorders needs robust biomarker and clinical endpoints to study drug efficacy in early and late stage trials. Ultimately, functional decline and motor disability are the main clinical manifestations of neuromuscular disorders (NMD) and used for approval of novel therapeutics. However, assessment of changes in neurological function is associated with large variability and many of the NMD are slowly progressive, thus limiting its feasibility as efficacy endpoint in early clinical development.

One of the most promising efficacy biomarkers in neuromuscular disorders for early clinical development is skeletal muscle MRI.  The recent development of quantitative skeletal MRI biomarkers, describing the extent of muscle atrophy and muscle fat infiltration and replacement, has enabled the detection and measurement of NMD earlier and more precisely compared to clinical endpoints. Standardized quantitative skeletal muscle MRI has been used to objectively evaluate NMD across different disease stages and measure longitudinal changes in diseases with complex onset patterns and slow progression such as FSHD (facioscapulomuscular dystrophy) and DMD (Duchenne Muscular Dystrophy).

In this webinar three experts will discuss various aspects of MRI biomarker development in NMD with a special focus on recent developments and experiences with MRI skeletal muscle biomarkers in DMD and FSHD:

  • Sarah Sherlock, PhD, Director Clinical and Translational Imaging, Pfizer
  • Diego Cadavid, MD, Senior Vice President, Clinical Development, Fulcrum Therapeutics
  • Per Widholm, MD, Lead Scientist, MSK, AMRA Medical Research

WHAT YOU WILL LEARN

  • How water and fat separated MRI has been used to describe disease stage and progression in neuromuscular disorders
  • Current examples on how quantitative MRI is used in neuromuscular trials
  • How whole-body MRI could improve the detection of treatment effect in NMD trials

FEATURED SPEAKERS

Sarah Sherlock, PhD, Director Clinical and Translational Imaging, Pfizer

Sarah Sherlock is a Director in the Digital Medicine & Translational Imaging Group at Pfizer based in Cambridge, MA.  In this role, she specializes in incorporating imaging biomarkers into clinical development plans with a focus on musculoskeletal and inflammatory diseases.  Since 2013, Sarah has focused on developing and executing an imaging strategy for Duchenne Muscular Dystrophy.  Prior to joining Pfizer, she worked at Parexel Informatics supporting MRI, CT, x-ray and DXA based studies.  Sarah has a B.A. in Chemistry from New College of Florida and a Ph.D. in Chemistry from Stanford University.

Diego Cadavid, MD, Senior Vice President, Clinical Development, Fulcrum Therapeutics
Diego Cadavid joined Fulcrum in September 2016. He brings more than 22 years of experience in academic and biotechnology research and drug development. Prior to joining Fulcrum, Diego was at Biogen for more than eight years, where he was senior medical director in the Multiple Sclerosis clinical development group and a director in the Neurology Clinical Group. During much of his time at Biogen, Diego was also a consultant at the Center for Immunology and Inflammatory Diseases at the Massachusetts General Hospital in Boston. Before joining Biogen, Diego spent nine years in academia at Rutgers-New Jersey Medical School, where he was an associate professor of neurology and neuroscience and worked on basic research on spirochetal brain infections and clinical research in multiple sclerosis. Diego completed postdoctoral research in microbiology and immunology and an internship in internal medicine at the University of Texas Health Science Center in San Antonio; neurology residency training at Georgetown University Hospitals; and a neuropathology fellowship at the Armed Forces Institute of Pathology. He has published over 100 papers and cited over 4,500 times.  Diego holds an M.D. from Universidad Javeriana in Bogotá, Colombia.

Per Widholm, PhD, Lead Scientist, MSK, AMRA Medical Research
Per Widholm is currently working as lead scientist in Musculoskeletal Conditions at AMRA Medical Research as a part of AMRA Medical. Before joining AMRA in 2017 he worked as a Musculoskeletal radiologist at Linköping University Hospital, Sweden. At AMRA he is leading the development of a novel analysis platform for volumetrical assessment of muscles using Whole-body Quantitative MRI. The team has successfully established a rapid and scanner independent scan protocol and a semi-automatic analysis chain that is capable of monitoring individual muscles throughout the body, easily adaptable for use in many different musculoskeletal diseases and disorders. Per has an M.D from Karolinska Institutet and did his radiology training at Linköping University Hospital where he currently is attaining his Ph.D. on Quantitative MRI in Musculoskeletal Disorders.

Get the recorded webinar via our Webinars section.

All posts
  • Facebook
  • Twitter
  • LinkedIn
  • Mail
AMRA Medical
Follow us

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

  • Data Privacy Policy
  • Cookie Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support

Newsletter

© 2025 AMRA Medical AB
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}